

Minireview papers

Leveraging on Prompt Proactive and Preventive Integrated Strategies for Meningitis Control in Nigeria

Abstract

Background: Given the escalating morbidity and mortality recorded annually due to meningitis outbreak in Nigeria, it is fast becoming a disease of public health concern.

Objectives: This study described and discussed preventive strategies based on the disease pattern to generate information on the concept of prompt, proactive, and preventive integrated strategies (PPPIS).

Methods: The study was a narrative overview of relevant literatures obtained through hand search, databases, and authoritative materials.

Results: Meningitis was reported in 5 states of Northern Nigeria with 1407 suspected cases and 211 deaths between January 2016 and March 2017. This figure rose to 13, 420 suspected cases in 23 states with 1, 069 deaths, and a fatality ratio of 8% in May 2017.

Conclusion: Meningitis has become an increasing contributor to disease burden with high mortality, morbidity, and economic consequences. Adoption of prompt, proactive, and preventive strategies among other integrated approach could stem and reverse the trend.

Keywords: Disease prevention, integrated approach, meningitis, Nigeria

Introduction

Meningitis is a medical emergency characterized by infection of the meninges with the presence of pus and inflammatory cells in the cerebrospinal fluid and marked with high morbidity and mortality. The causative organisms vary from bacteria, to virus, fungus, protozoa, chemicals, or neoplasia depending on patients' age. However, epidemic meningitis is usually associated with *Neisseria meningitidis*. Clinical features include vomiting, fever, headache, photophobia, and alterations in level of consciousness. Other features include fever of unknown origin, stroke-like syndrome, seizures, acute psychosis, and dementia. Complications vary from subdural pus collection, cranial nerve palsies, epilepsy, heat stroke, and syndrome of inappropriate anti-diuretic hormone secretion. It is a major cause of morbidity and mortality especially among children in developing countries [1-6].

Approximately 8.7 million people were affected by meningitis globally leading to 379000 deaths in 2015 and 464000 deaths in 1990 [7, 8]. It was known to be prevalent in Europe and America between 1805 and 1874, and became prevalent in Asia, Africa, and Australia in 1875. In sub-Saharan Africa, seasonal hyper-endemicity is recorded at the peak of dry season between

January and May before the onset of rainy season within the African meningitis belt. Weekly incidence rates of 10/100 000 has been recorded and sometimes exceeded 100/100 000 locally [9-12]. The first incidence was reported in Algeria in 1840 [13]. In late 18th century and early 19th century, the epidemic was reported in the western coast of Africa at Cape Coast [14, 15]. PPPIS entails the use of the right proactive and preventive strategies promptly for the right disease prevention or control in a continuum while leveraging on all available and rational preventive and treatment measures. This study described and discussed preventive strategies based on the disease pattern to generate information on the concept of prompt, proactive, and preventive integrated strategies (PPPIS).

Methods

This study was synthesized with information obtained from PubMed, Medline, hand search of related reference materials, and official documents. The search took place between December 2016 and March 2017. The search terms were meningitis, control, prevention, Disease prevention, integrated approach, and Nigeria. The search terms were used individually and in series using AND/OR. Truncation and adjacency searching were employed. Publications in English Language with unambiguous and clearly detailed methods were considered. All studies without clearly defined and logical methods were excluded.

Results

Nigeria was ranked 187 of the 191 countries in the world rated scale for health system in 2016. The life expectancy at birth for male/female was 53/56 in 2015. The total expenditure on health per capita (Intl \$, 2014) was 214 while the total expenditure on health per capita (Intl \$, 2014) was 217, and Total expenditure on health as percentage of GDP (2014) was 3.7. Table 1 below summaries meningitis outbreak in Nigeria from 1996 to 2017.

61 **Table 1: A summary of Meningitis outbreak in Nigeria**

Year	Month	Suspected cases	Deaths	Location (State)
1996	December to June	108, 568		
1996		15, 733	2411	12 states: Adamawa, Bauchi, Benue, Cross River, Kano, Kaduna, Katsina, Kebbi, Kwara, Niger, Sokoto, and Taraba.
2003/4	December to June	659		
2004	January to March	327	46	Jigawa
2005	January to June	657		
2006	January to June	5731		
2007	January to June	2642		
2008	December to June	6835		
2009	December to June	128	2000	5 states in north west and north central
2009	January to February	5323	333	
2009	December to June	54766	2449	16 northern states
2010	December to June	2983		
2011	December to June	1165		
2012	December to June	1206		
2013	December to June	871		
2013/14	December to June	128	2046	
2015	January to March	652	50	Kebbi and Sokoto
2016	December to June	300	336	
2017	March	12000	211	5 States: Kastina, Sokoto, Zamfara, Kebbi, and Niger
2017	January to March	1966	282	15 states 
2017	January to May	13420	1069	23 states

62 December to June: This represents **from December** of the previous year to December of present year

63 Discussion

64 Nigeria has witnessed major epidemic outbreak of meningitis from 1970 to 2017. However, the
 65 highest prevalence was recorded in first half of 1996 when 109, 580 cases were reported out of
 66 which 11, 717 died [16, 17]. From December 2016 to March 2017, epidemiological survey of
 67 meningitis in 5 states of Northern Nigeria revealed 1407 suspected cases and 211 deaths, a case
 68 fatality rate of 15%. By April 2017, the 6 states of Sokoto, Kebbi, Kastina, Yobe, Zamfara, and
 69 Niger were affected with an estimated 8,057 suspected cases, 230 confirmed cases and 813
 70 deaths, an epidemic threshold. Children within the age of 5 to 14 years were predominantly
 71 affected and constituted more than half of the suspected cases [18-20]. Of the 230 confirmed
 72 cases, 157 were confirmed with serotype C of *Neisseria meningitides*. This same serotype was
 73 found to be responsible for the 2014 and 2015 outbreaks in Nigeria. Other strains of *Neisseria*

meningitidis namely A, B, W, and Y which cause meningitis globally have been unpopular in Nigeria except serotype A whose vaccine is available [21, 22]. On the second week of May 2017, 13, 420 suspected cases were reported in 23 states with 1, 069 deaths, and fatality ratio of 8% [23].

The number of suspected cases and death has been relatively high though irregular as shown in Table 1. This underscores the need for strategies to contain and begin to reverse the trend. Its predominant localization to key states in the northwest and north central could be utilized in concentrating efforts during prevention and control without prejudice to other states. Table 1 further suggests inconsistency in documentation of data e.g., documentation of yearly number of deaths may have been inconsistent. Consistencies in documentation helps in proper audit trail and follow up. It is invaluable in quantification for programs and services. Meningitis occurs predominantly between December and June during dry season in Nigeria characterized by high temperature distribution. *Neisseria* spp, *Haemophilus influenzae*, *Streptococcus pneumonia* have been implicated in the outbreak of meningitis over the years while *Neisseria meningitidis* sero group A caused epidemics in the past [24-27]. This information underscores the need for sustained and massive immunization campaign drive and coverage. The disease control unit necessary for immunization should not continue with the reactive approach of immunization response or coverage when cases have reached near epidemic dimension, proactive response is of great essence with the requisite conjugate vaccines covering the serotypes. Hence, the threshold strategy that allows the disease to progress to detectable threshold. Provisions should be made for identified serotypes, which the vaccines could not cover adequately to take care of reactive cases. This process should be maintained in a continuous cycle [28-33].

This should be tailored to sustained vaccines supply with quality assurance measures to ensure good quality and stability while maintaining good tracking of monitoring and evaluation in the immunization coverage. Disease surveillance update should be prompt and regular to detect and report initial cases promptly. Preference should be given to prophylactic conjugate vaccines with additional property of limiting transmission while conferring long lasting immunity [34-37]. The influence of socio-cultural determinants is disease should be considered as another means of epidemic control. Some tribes where vaccinees refuse to accept vaccines from immunization vaccinators of opposite gender could be a limiting factor. Others where permission has to be taken from the family head before their subjects could access immunization all combine to adversely affect immunization coverage [38-39]. These could be addressed through routine interaction of relevant authorities with village heads and their subjects based on the principle of health education and community mobilization. Mumps meningitis, which occurs in 15% of mumps cases, recorded marked decline following prompt immunization against mumps [40].

Socioeconomic and demographic factors have been noted as another cause to be critically considered. Overcrowding and poor living conditions is common among outbreak locations. This is very common among pilgrims, military camps, refugee camps, internally displaced people's camp, and slums. Countries like Sudan, Chad, and Morocco have recorded meningitis outbreaks associated with returning pilgrims in 1988, 1988, and 1989 while Saudi Arabia had a similar case in 1987. This underscores the need to observe global best practices at every port of entry and immigration points in line with international health recommendations considering that diseases cross borders. The attack rate of most meningitis epidemics in sub-Saharan Africa exceed 1% before being reported. There is dire need follow the trend of most developed countries where it is much lower through improved warning systems and early detection of localized and widespread epidemics, regular data review, prompt reporting and rapid communication, investigation of affected cases, case definition, rapid assessment, and information dissemination across board [41- 43]. Preventive strategies should be proactive to be effective. Any preventive mechanism in disease control no matter how expensive or effective can lead to loss of lives and disabilities if it is not prompt. A proactive preventive mechanism that is not prompt will also be limited. Hence, the principle of Prompt, Proactive, and Preventive Integrated Strategies (PPSIS) should never be compromised. This will help to prevent or minimize casualties in supposed epidemic outbreak. Strengthening health systems through the primary healthcare development agency and inter sectoral collaboration. Development and implementation of a comprehensive National Strategic Health Development Plan (NSHDP) through the National Health Bill and scaling up meningitis intervention plan as one of the priority interventions could be a booster to the entire mechanism.

Conclusion

Meningitis has become a major contributor of disease burden in Nigeria annually. High incidence of fatality that occurs annually despite reasonable information on the disease trend and patterns occasioned the need to consider salient preventive mechanisms. The concept of Prompt and Proactive Preventive Integrated Strategies (PPPS) is essential in forestalling disease outbreaks from progressing to epidemic dimensions. All preventive mechanisms must be prompt, proactive, prompt, and integrated leveraging on all existing strategies. This approach should be applied in a continuum and repeated uninterrupted cycles in meningitis prevention and control for meaningful outcomes to be achieved. Given the rising trend of morbidity and mortality associated with meningitis in Nigeria, integrated strategies in its prevention should be prompt, proactive, and maintained in a continuum among other integrated approach could stem and reverse the trend.

149 **References**

- 150 1. Amarilyo G, Alper A, Ben-Tov A, Grisaru-Soen G. Diagnostic accuracy of clinical
151 symptoms and signs in children with meningitis. *Pediatr Emerg Care*. 2011; 3:196–9.
- 152 2. Lagunju IA, Falade AG, Akinbami FO, Adegbola R, Bakare RA. Childhood bacterial
153 meningitis in Ibadan, Nigeria – Antibiotic sensitivity pattern of pathogens, prognostic
154 indices, and outcome. *Afr J Med Sci*. 2008; 37:185–91.
- 155 3. Tunkel AR; Hartman BJ; Kaplan SL; et al. "Practice guidelines for the management of
156 bacterial meningitis" (PDF). *Clinical Infectious Diseases*. 2004; 39 (9): 1267–
157 84. doi:10.1086/425368. PMID 15494903.
- 158 4. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF (January 2006). "Community-acquired
159 bacterial meningitis in adults". *The New England Journal of Medicine*. 354 (1): 44–
160 53. Doi: 10.1056/NEJMr052116. PMID 16394301.
- 161 5. Attia J, Hatala R, Cook DJ, Wong JG. "The rational clinical examination. Does this adult
162 patient have acute meningitis?". *Journal of the American Medical Association*. 1999;
163 282 (2): 175–81. Doi: 10.1001/jama.282.2.175. PMID 10411200.
- 164 6. Thomas KE, Hasbun R, Jekel J, Quagliarello VJ. "The diagnostic accuracy of Kernig's sign,
165 Brudzinski neck sign, and nuchal rigidity in adults with suspected
166 meningitis" (PDF). *Clinical Infectious Diseases*. 2002; 35 (1): 46–52. Doi:
167 10.1086/340979. PMID 12060874.
- 168 7. GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global,
169 regional, and national life expectancy, all-cause mortality, and cause-specific mortality
170 for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of
171 Disease Study 2015." *Lancet*. 388 (10053):1459–1544. Doi: 10.1016/s0140-
172 6736(16)31012-1. PMID 27733281.
- 173 8. GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global,
174 regional, and national age-sex specific all-cause and cause-specific mortality for 240
175 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease
176 Study 2013." *Lancet*. 385 (9963):117–71. Doi: 10.1016/S0140-6736(14)61682-
177 2. PMC 4340604 . PMID 25530442.
- 178 9. Hassabu M. Historical background and epidemiology of cerebrospinal meningitis
179 (CSM). *Sudan J Paediatr* 2013, 13(2):115-123.
- 180 10. Mueller JE., Gessne BD. A hypothetical explanatory model for meningococcal meningitis
181 in the African meningitis belt. *Int J Infect Dis*. 2010; 14: e553–e559.
- 182 11. Greenwood BM. Meningococcal meningitis in Africa. *Trans R Soc Trop Med Hyg*. 1999;
183 93: 341-353.
- 184 12. Mueller JE., Yaro S., Ouédraogo MS., Levina N., Njanpop-Lafourcade BM., Tall H. *et al*.
185 Pneumococci in the African meningitis belt: meningitis incidence and carriage

- 186 prevalence in children and adults. *PLoS*
187 *One*. 2012; 7: e52464DOI: <http://dx.doi.org/10.1371/journal.pone.0052464>.
- 188 13. Chalmer AJ, O'Farrell WR. Preliminary remarks upon epidemic cerebrospinal meningitis
189 as seen in the Anglo-Egyptian Sudan Journal of Tropical Medicine and Hygiene. 1916;
190 101-129.
- 191 14. Williams EGG, Williams MH. Cerebrospinal Meningitis. Journal of Tropical Medicine.
192 1900; 3: 83-85.
- 193 15. Williams EGH, Williams MH. Cerebrospinal Meningitis. Journal of Tropical
194 Medicine.1901; 4: 22-23.
- 195 16. Idris M, Abdussalam N, Abba A, Suleiman A. A severe epidemic of meningococcal
196 meningitis in Nigeria. Article in Transactions of the Royal Society of Tropical Medicine
197 and Hygiene 94(3):265-70 · May 2000. DOI: 10.1016/S0035-9203(00)90316-X.
- 198 17. Clément LC, Bergeron-Caron C, Stuart JM, Fernandez K, Mamoudou HD, Ronveaux O,
199 Schnitzler JC, Perea WA. Meningococcal Meningitis Surveillance in the African
200 Meningitis Belt, 2004–2013. S410. CID 2015:61 (Suppl 5).
- 201 18. Case count of meningitis outbreak in Nigeria. Accessed on 2 May 2017 at
202 <http://outbreaknewstoday.com/nigeria-meningitis-case-count-tops-8000/>
- 203 19. Emergencies of meningitis in Nigeria. Accessed on 2 May 2017
204 at<http://www.who.int/emergencies/nigeria/meningitis-c/en/>
- 205 20. Meningococcal disease in Nigeria. Accessed on 4 May 2017
206 at <https://wwwnc.cdc.gov/travel/diseases/meningococcal-disease>.
- 207 21. Greenwood B. 100 years of epidemic meningitis in West Africa- has anything
208 changed? Tropical Medicine and International Health, 2006; 11(6), 773–780.
- 209 22. Meningococcal disease in Nigeria. Accessed on 11 April 2017
210 at<http://www.who.int/csr/don/24-march-2017-meningococcal-disease-nigeria/en/>
- 211 23. 1069 Nigerians have died of meningitis. Accessed on 12 May 2017 at
212 <http://www.swankpharm.com/2017/05/12/1069-nigerians-died-meningitis/>
- 213 24. LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group
214 A *Neisseria meningitidis* in the African meningitis belt: a persistent problem with an
215 imminent solution. Vaccine. 2009; 27(Suppl. 2):B13–9.
- 216 25. Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis
217 in the African meningitis belt. Int J Infect Dis. 2010; 14:e553–9.
- 218 26. Broutin H, Philippon S, de Magny GC, et al. Comparative study of meningitis dynamics
219 across nine African countries: a global perspective. Int J Health Geogr. 2007; 6:6–29.

- 220 27. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal
221 disease. *Vaccine*. 2009; 27(Suppl.2):B51–63.
- 222 28. Kieny MP, LaForce EM. The promise of conjugate vaccines for Africa. *Vaccine*. 2007;
223 25(Suppl. 1):A108–10.
- 224 29. WHO. Geneva: WHO; 2001. WHO strategy for prevention and control of meningococcal
225 disease in Africa.
- 226 30. Leake JAD, Kone ML, Yada AA, et al. Early detection and response to meningococcal
227 disease epidemics in sub-Saharan Africa: appraisal of the WHO strategy. *Bull*
228 *WHO*. 2002; 80:342–9.
- 229 31. Pinner RW, Onyango F, Perkins BA, et al. Epidemic meningococcal disease in Nairobi,
230 Kenya, 1989. *J Infect Dis*. 1992; 166:359–64.
- 231 32. Lewis R, Nathan N, Diarra L, et al. Timely detection of meningococcal meningitis
232 epidemics in Africa. *Lancet*. 2001; 358:287–93.
- 233 33. Ferrari MJ, Fermon F, Nackers F, Llosa A, Magone C, Grais RF. Time is (still) of the
234 essence: quantifying the impact of emergency meningitis vaccination response in
235 Katsina State, **Nigeria**. *Int Health*. 2014 Dec; 6(4): 282–290.
236 Doi: 10.1093/inthealth/ihu062
- 237 34. Vestrheim DF, Hoiby EA, Aaberge IS, Caugant DA. Impact of a pneumococcal conjugate
238 vaccination program on carriage among children in Norway. *Clin Vaccine*
239 *Immunol*. 2010; 17:325–34.
- 240 35. Moore MR, Hyde TB, Hennessy TW, et al. Impact of a conjugate vaccine on community-
241 wide carriage of nonsusceptible *Streptococcus pneumoniae* in Alaska. *J Infect Dis*. 2004;
242 190:2031–8.
- 243 36. Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after
244 meningococcal C conjugate polysaccharide vaccination. *Lancet*. 2002; 359:1829–30.
- 245 37. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal
246 serogroup C conjugate vaccination in England: database analysis. *Br Med J*. 2003;
247 326:365–6.
- 248 38. Burki T. Meningitis outbreak in Niger is an urgent warning. *Lancet Infect Dis*. 2015 Sep;
249 15(9):1011. PubMed PMID: 26333332.
- 250 39. World Health Organization Inter country support team – West Africa. Meningitis weekly
251 bulletin December 2015. Retrieved on May 05, 2016. Accessed on 4 May 2017 at
252 http://www.who.int/crs/disease/meningococcal/bulletin_Meningitis_s49_53_2015.pdf
- 253 40. Logan SA, MacMahon E. "Viral meningitis". *BMJ (Clinical research Ed.)*. 2008;
254 **336** (7634):36–40. Doi: 10.1136/bmj.39409.673657.AE. PMC 2174764 
255 . PMID 18174598.

- 256 41. World Health Organization (WHO). Emerging and other Communicable Diseases,
257 Surveillance, and Control WHO/EMC/BAC/98.3 Control of epidemic meningococcal
258 disease. WHO practical guidelines. 2nd edition. Accessed on 2 May 2017 at
259 <http://www.who.int/emc> for more information.
- 260 42. Greenwood BM. The epidemiology of acute bacterial meningitis in tropical Africa. In:
261 Williams JD, Burnie J (Eds), *Bacterial meningitis*. London, Academic Press, 1987:61-91.
262 Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. *Clin*
263 *Microbiol Rev* 1989; 2(supplement):S118- S124.
- 264 43. Tikhomirov E, Santamaria M, Esteves K. Meningococcal disease: public health burden
265 and control. *World Health Stat Q* 1997; 50(3/4):170-177.